Half-Year 2022 Financial and Clinical Trials Update

Ronapreve Global sales CER growth Regional sales CER growth CHFbn +11% 0.7 International -30% 0.6 0.5 Europe -86% 0.4 0.3 Japan n/a 0.2 0.1 0.0 HY 19 HY 20 HY 21 HY 22 HY 2022 sales of CHF 609m · EU: Limited sales potential left as Ronapreve has low activity against Omicron variants . Japan: Additional sales to the government (overall CHF 1.6bn for FY 2022) CER-Constant Exchange Rates Roche 181

View entire presentation